Susquehanna International Group, LLP Bio Line Rx Ltd. Put Options Transaction History

Susquehanna International Group, LLP

4 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 15, 2024	SELL	$0.56 - $0.86 $34,496 - $52,976	-61,600 Reduced 35.79%	110,500 $62,000
Q1 2024 May 07, 2024	BUY	$1.03 - $1.56 $48,925 - $74,100	47,500 Added 38.12%	172,100 $192,000
Q4 2023 Feb 14, 2024	BUY	$1.31 - $1.86 $28,296 - $40,176	21,600 Added 20.97%	124,600 $195,000
Q3 2023 Nov 14, 2023	BUY	$1.23 - $2.45 $126,690 - $252,350	103,000 New	103,000 $187,000

3.3M

46.5K

6.3K

Ticker BLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,524,500
Market Cap $29.5M
Description
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.